Search
Searching Content indexed under Food and Drugs Law by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP ordered by Published Date Descending.
Links to Result pages
 
1 2 3 4 5  
>>Next
 
Title
Country
Organisation
Author
Date
1
Considerations In Demonstrating Interchangeability With A Reference Biologic Product
Dek: Sponsors should seek early discussions with FDA to ensure an effective and efficient process for demonstrating the interchangeability of a chosen biologic product
United States
20 Aug 2019
2
New FDA Guidance On Biosimilar Interchangeability
On May 09, 2019, the U.S. FDA issued final guidance titled "Considerations in Demonstrating Interchangeability with a Reference Product." It is intended to assist sponsors in demonstrating
United States
22 Jul 2019
3
The Amazing Story Of The Unsinkable Claim 8: How Many Lives Does A Patent Claim Have?
Decision: Mylan Pharmaceuticals Inc. v. Research Corporation Technologies, Inc., 914 F.3d 1366 (Fed. Cir. 2019) (LOURIE, Bryson, Wallach)
United States
19 Jul 2019
4
A Piece Of Federal Circuit History: It's A Little Cheesy
One of the most cited decisions issued by the Federal Circuit is University of Notre Dame Du Lac v. J.C. Gourmet Food Co., Inc., 703 F.2d 1372 (Fed. Cir. 1983).
United States
11 Jun 2019
5
Summary Of Final Guidance On Interchangeability Of Biosimilars With Reference Products
On May 10, 2019, the U.S. Food and Drug Administration (FDA) released nonbinding final Guidance for Industry.
United States
10 Jun 2019
6
FDA Final Guidance On Application Of Statutory Factors In Determining When A REMS Is Necessary
On April 4, 2019, FDA issued final guidance on FDA's application of the statutory factors in determining when a risk evaluation and mitigation strategy (REMS) is necessary.
United States
30 Apr 2019
7
Battle Of The Beers—Can Anheuser's Bud Light Ads Be Literally True But Legally False?
Beer. An alcoholic beverage traditionally made with four ingredients: water, barley, yeast, and hops. But what about corn syrup?
United States
22 Apr 2019
8
FDA Procedures For Handling Requests For Nonproprietary Name Suffix Review For Biological Products Newly Licensed Under Section 351 Of The PHS Act
On March 7, 2019 FDA updated the Center for Drug Evaluation and Research (CDER) Manual of Policies on Procedures (MAPP) for Nonproprietary Naming of Biological Products.
United States
1 Apr 2019
10
FDA Commissioner's Statement On Plans For The Orange Book
After dropping hints in recent months that he intended to use creative policy efforts to promote competition in the American pharmaceutical industry, U.S. Food and Drug Administration Commissioner Scott Gottlieb...
United States
28 Mar 2019
11
FDA Final Guidance On Developing Buprenorphine Treatments For Opioid Use Disorder
On February 13, 2019, FDA issued final guidance on developing depot buprenorphine products for treatment of opioid use disorder.
United States
27 Feb 2019
12
Patent The Internet Of Things (IoT) In The Food Industry
The "internet of things" (IoT) is revolutionizing how people live and work. Each day, the IoT grows as companies look for even more ways to connect devices with the goal of collecting and reporting
United States
14 Feb 2019
13
FDA Commissioner Statement About The Orange Book
On January 30, 2019, FDA Commissioner Scott Gottlieb issued a statement on FDA's efforts to enhance the utility of the Orange Book to foster drug competition.
United States
14 Feb 2019
14
A Tale Of Two Macs: If You Don't Provide Evidence Does A Big Mac Exist?
In a whopper of a decision, the Cancellation Division of the EU Intellectual Property Office ("EUIPO") revoked McDonald's BIG MAC EU trade mark registration.
United States
13 Feb 2019
15
FDA Final Guidance On Immunogenicity Testing Of Therapeutic Protein Products
On January 23, 2019, FDA issued final guidance on immunogenicity testing of therapeutic protein products.
United States
4 Feb 2019
16
FDA Draft Guidance On Common Issues In Drug Development For Rare Diseases
On January 16, 2019, FDA issued draft guidance on Rare Diseases: Common Issues in Drug Development. The FDA intends the guidance to help sponsors conduct more efficient ...
United States
29 Jan 2019
17
Five Most Popular IP FDA Blog Posts From 2018
Happy New Year! In case you missed them, here are our five most popular posts from 2018. This has been an exciting year for the Finnegan IP FDA Blog ...
United States
17 Jan 2019
18
Inherency And Obviousness
This case provides an example of the use of inherency in an obviousness determination. That is, the Northern District Court of Illinois found that claim 6 of U.S. Pat. 8,648,106 (the '106)
United States
7 Jan 2019
19
FDA Proposed Rule Defining "Biological Product"
If finalized, the rule would take effect on the earlier of 60 days after publication in the Federal Register or March 23, 2020.
United States
3 Jan 2019
20
First Revision To Questions And Answers On Biosimilar Development
On December 11, 2018, FDA issued its fifth final guidance document related to the development of biosimilars and interchangeability products entitled Questions and Answers on Biosimilar
United States
28 Dec 2018
Links to Result pages
 
1 2 3 4 5  
>>Next